Amkay Products Limited (BSE SME)
Apr 30, 2024 - May 3, 2024
| Price | ₹52 - ₹55 |
| Premium | ₹62 |
|---|---|
| Lot size | 2000 |
| Allotment | May 6, 2024 |
| Listing | May 8, 2024 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 2000 | 110000 | 381 |
| HNI | 2 | 4000 | 220000 | 163 |
Last updated on 03 May 2024 | 05:55:03 PM
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 434000 | 75098000 | 173.04 |
| HNIs | 326000 | 321994000 | 987.71 |
| Retail | 762000 | 741530000 | 973.14 |
| Total | 1522000 | 1138622000 | 748.11 |
| Total Application : 510,613 | |||
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹72.93 | @8% ₹83.35 | @9% ₹93.76 | @10% ₹104.18 | @11% ₹114.6 | @12% ₹125.02 |
Anchor List
| Name of Anchor | No. of Shares | % Portion | Amount (cr) |
|---|---|---|---|
| Visionary Value Fund | 4,10,000 | 63.08% | 2.26 |
| Meru Investment Fund PCC-Cell 1 | 2,40,000 | 36.92% | 1.32 |
| Total | 650000 | 100.00% | 3.58 |
IPO Reservation
| Investor Category | Shares Offered | No. of Shares |
|---|---|---|
| Retail | 33.25% | 762000 |
| NII (HNI) | 14.22% | 326000 |
| QIB | 18.93% | 434000 |
| Anchor | 28.35% | 650000 |
| Market Maker | 5.24% | 120000 |
| Total | 100.00% | 2292000 |
Founded in October 2007, Amkay Products Limited has emerged as a prominent name in India's healthcare industry, specializing in the production and distribution of an extensive range of medical supplies. Their offerings encompass a diverse portfolio, including medical devices like nebulizers and pulse oximeters, alongside essential disposables such as face masks and alcohol swabs. With a commitment to quality, Amkay's manufacturing facility, situated across two units in Thane, Maharashtra, spans an impressive 26,000 square feet. These facilities are equipped with state-of-the-art machinery, a meticulous testing laboratory, and comprehensive handling equipment, ensuring seamless production processes. Notably, the company's adherence to stringent quality management practices has earned it accreditation under the ISO 9001:2015 standard by QRO Certification LLP. Despite the challenges posed by the dynamic healthcare landscape, Amkay Products Limited remains steadfast in its mission to deliver excellence. As of December 31, 2023, the company proudly employs around 75 dedicated professionals across various organizational levels, underscoring its commitment to fostering a talented workforce. Through its unwavering dedication to innovation, quality, and customer satisfaction, Amkay continues to play a pivotal role in meeting the healthcare needs of institutions nationwide.
Amkay Products IPO Details
| Issue Size | 2,292,000 shares (aggregating up to ₹12.61 Cr) |
| Fresh Issue | 2,292,000 shares (aggregating up to ₹12.61 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE SME |
| Share holding pre issue | 6,363,640 |
| Share holding post issue | 8,655,640 |
| Market Maker portion | 120,000 shares Hem Finlease |
Key Performance Indicator
| KPI | Dec-23 | Mar-23 | Mar-22 |
|---|---|---|---|
| ROE | 24.49% | 21.69% | 26.81% |
| ROCE | 21.54% | 22.61% | 22.88% |
| RONW | 21.82% | 19.57% | 23.64% |
| D/E | 0.48 | 0.61 | 0.7 |
| EPS (basic & Diluted) | 3.38 | 2.37 | 2.31 |
| P/BV | 3.55 | ||
| P/E Pre IPO | 23.18 |
Company Financials
Amkay Products Limited Financial Information (Restated)
Amkay Products Limited's revenue decreased by -23.22% and profit after tax (PAT) rose by 2.94% between the financial year ending with March 31, 2023 and March 31, 2022.
| Period | Dec 2023 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
| Assets | 1,887.52 | 1,563.77 | 1,580.64 | 1,393.47 |
| Revenue | 2,385.56 | 2,825.05 | 3,679.45 | 4,071.74 |
| Profit | 215.34 | 151.02 | 146.71 | 312.68 |
| Net Worth | 986.96 | 771.62 | 620.60 | 473.90 |
| Reserves | 350.59 | 743.95 | 592.93 | 446.23 |
| Borrowing | 476.22 | 469.98 | 433.59 | 136.54 |
| Amount in ₹ Lakhs | ||||
Strength factors
Stringent Quality Assurance: The company's adherence to rigorous quality management practices, accredited under ISO 9001:2015, ensures standardized product quality, instilling confidence in customers and stakeholders alike.
Diversified Revenue Streams: With a presence in multiple geographies, Amkay enjoys diversified revenue streams, mitigating risks associated with market fluctuations and enhancing resilience against economic uncertainties.
Experienced Leadership: Bolstered by an experienced promoter and a seasoned senior management team with a proven track record and deep industry knowledge, Amkay is strategically positioned to navigate challenges and capitalize on emerging opportunities effectively.
Risk Factors
Declining Revenue Trend: Persistent decline in revenue over the past two financial years raises concerns about the company's ability to sustain profitability and maintain market competitiveness amidst evolving industry dynamics and economic challenges.
Historical Negative Cash Flows: Historical instances of negative operating, investing, and financing cash flows indicate potential liquidity constraints and financial instability, posing risks to the company's operational sustainability and capital investment capabilities.
Potential Future Operating Losses: Continued operating losses or negative cash flows in the future could significantly impair Amkay's results of operations and financial condition, hampering its ability to meet debt obligations, invest in growth initiatives, and sustain shareholder value. Such scenarios may also erode investor confidence and hinder the company's access to capital markets for necessary funding.
Amkay Products IPO Lead Manager(s)
- Hem Securities Limited
Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/ipo_status.html